ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results